Oncothyreon promotes Diana Hausman to CMO
This article was originally published in Scrip
Dr Diana Hausman has been promoted to chief medical officer of Oncothyreon, a biotechnology company developing therapeutic oncology products. Dr Hausman joined Oncothyreon in August 2009 as vice-president of clinical development. She was previously employed at Zymogenetics as senior director of clinical research.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.